Journal of the American Academy of Dermatology · 1997
The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis.
СтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Thiers B H
Аннотация
BACKGROUND: Topical calcipotriene ointment has been approved for the treatment of plaque-type psoriasis.
OBJECTIVE: This article explores the possible use of topical calcipotriene ointment in the treatment of nail and intertriginous psoriasis, palmoplantar and pustular psoriasis, Reiter's syndrome, pityriasis rubra pilaris, and disorders of keratinization.
METHODS: The recent literature is reviewed.
RESULTS: Recent reports suggest that certain ichthyoses (particularly the hyperproliferative variants) and keratodermas may respond to topical calcipotriene ointment. The activity of calcipotriene relates to a dose-dependent decrease in proliferation and an increase in terminal differentiation of keratinocytes.
CONCLUSION: Patients with other disorders characterized by epidermal hyperproliferation may also be candidates for treatment. The use of calcipotriene in treating congenital hyperproliferative disorders is limited by the theoretical risk of hypercalcemia from absorption of the drug after application to extensive areas of skin.
OBJECTIVE: This article explores the possible use of topical calcipotriene ointment in the treatment of nail and intertriginous psoriasis, palmoplantar and pustular psoriasis, Reiter's syndrome, pityriasis rubra pilaris, and disorders of keratinization.
METHODS: The recent literature is reviewed.
RESULTS: Recent reports suggest that certain ichthyoses (particularly the hyperproliferative variants) and keratodermas may respond to topical calcipotriene ointment. The activity of calcipotriene relates to a dose-dependent decrease in proliferation and an increase in terminal differentiation of keratinocytes.
CONCLUSION: Patients with other disorders characterized by epidermal hyperproliferation may also be candidates for treatment. The use of calcipotriene in treating congenital hyperproliferative disorders is limited by the theoretical risk of hypercalcemia from absorption of the drug after application to extensive areas of skin.
Предметные рубрики MeSH
Administration, TopicalArthritis, ReactiveCalcitriolCell DifferentiationCell DivisionDermatologic AgentsDose-Response Relationship, DrugFoot DermatosesHand DermatosesHumansHypercalcemiaIchthyosisKeratinocytesKeratosisNail DiseasesOintmentsPityriasis Rubra PilarisPsoriasisSkin AbsorptionSkin Diseases